Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
Grifols has officially launched FESILTY (fibrinogen, human-chmt) in the United States, making its new fibrinogen concentrate available to patients with congenital fibrinogen deficiency. The product, which received FDA approval in December 2025, is indicated for treating acute bleeding episodes in pediatric and adult patients with hypo- or afibrinogenemia, but not for dysfibrinogenemia.
Key figures
- Drug Name
- FESILTY (fibrinogen, human-chmt)
- Storage condition
- room temperature
- Reconstitution time
- approximately three minutes
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.